AnaptysBio, Inc. (FRA:AN6)

Market Cap	1.10B +141.5%
Revenue (ttm)	144.44M +196.4%
Net Income	-72.13M
EPS	-2.45
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	41.20
Previous Close	41.00
Day's Range	41.20 - 41.20
52-Week Range	11.80 - 43.80
Beta	n/a
RSI	50.88
Earnings Date	Mar 2, 2026

About AnaptysBio

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and I...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2005
• Employees: 136
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: AN6

Financial Performance

In 2024, AnaptysBio's revenue was $91.28 million, an increase of 432.03% compared to the previous year's $17.16 million. Losses were -$145.23 million, -11.24% less than in 2023.

Financial numbers in USD